Stocks to sell

I recommended Moderna (NASDAQ:MRNA) stock in late 2020 as part of a decade-long trend.  But MRNA stock has been taken over by events surrounding the company’s COVID-19 vaccine. Source: Shutterstock Through the first three quarters of 2021, Moderna racked up $11.26 billion in sales. Analysts expect another $5.9 billion to come rolling in for Q4.
In recent weeks, QuantumScape (NYSE:QS) has made significant progress, improving the company’s outlook. Still, the valuation of QS stock remains very high, and the company continues to face major risks. Source: Michael Vi / Shutterstock.com Among these risks, as Morgan Stanley recently pointed out, are tough competition and the possibility that the production of electric
Deciphera Pharmaceuticals (NASDAQ:DCPH) is a biotech company that develops drugs mainly for the treatment of cancer. Right now, DCPH stock shares are down nearly 85% year-to-date (YTD), at $7.70 as of the close of Nov. 29. Source: Iryna Imago / Shutterstock.com Of course, with Thanksgiving just over, it’s probably appropriate to note that I’m thankful for
When you chase after a stock that has gone too far without justification, you’re likely to get punished. That’s a lesson learned by many of Jumia Technologies’ (NYSE:JMIA) shareholders, as JMIA stock has been taking a beating lately. Source: farzand01 / Shutterstock.com As the old saying goes, the trend is your friend. There’s nothing friendly about
SoFi Technologies (NASDAQ:SOFI) is a fintech company seeking to disrupt the traditional banking market. SOFI stock officially launched earlier this year after it completed a merger with one of Chamath Palihapitiya’s special purpose acquisition companies (SPACs). Source: rafapress / Shutterstock.com Out of the gate, SoFi generated a lot of excitement. Unlike some of its fintech
For the last few months I have been warning investors away from Vinco Ventures (NASDAQ:BBIG) stock. Since my first story came out in September, the shares are down 67%. They closed November 23 at $3.13. Source: shutterstock.com/Postmodern Studio My problem with the company is that there is nothing there. It’s all hype and buzzwords like streaming
Although Gevo (NASDAQ:GEVO) made a few positive deals recently and it could benefit from multiple government initiatives, the company is still facing difficult hurdles. Moreover, the valuation of GEVO stock remains elevated, given the company’s uncertain outlook. Source: Scharfsinn / Shutterstock.com As a result of the company’s challenges and weaknesses, along with its high valuation,
Buying stocks on dips can sometimes be a profitable strategy. However, grabbing shares of Paysafe (NYSE:PSFE) could be harmful to your fiscal health, as PSFE stock has entered into a harsh and persistent bear market. Source: Sulastri Sulastri / Shutterstock.com If you abide by the principle of “the trend is your friend,” then there’s nothing
With Thanksgiving and other winter holidays fast approaching, it’s a good practice to stop and consider what we’re grateful for. When it comes to the professional realm, I’m appreciative for the ability to get paid for crafting (hopefully) compelling stories. Through this journey, I’ve reached out to millions and even make regular TV appearances. But